Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus

Maria B. Grant, Connie Fitzgerald, Colleen Guay, Richard Lottenberg

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor, (PAI), and von Willebrand factor (vWF) were measured in 30 diabetics and 17 control subjects. These studies were performed to clarify the role of obesity in causing abnormalities of the fibrinolytic system in diabetics. The t-PA antigen response measured after the infusion of desmopressin acetate (DDAVP) was similar in all groups. Peak responses to DDAVP for controls, type I diabetics, and type II diabetics were 21.2 ± 9.5 ng/mL, 27.5 ± 9.0 ng/mL, and 28.8 ± 11.0 ng/mL (NS), respectively. These responses did not correlate with the body mass index (BMI) or any other of the indices examined. A significant decrease of t-PA activity as contrasted with t-PA antigen following DDAVP occurred in type II diabetics only. The decrease of t-PA activity strongly correlated with greater basal levels of plasminogen activator inhibitor in these same subjects. The plasma level of plasminogen activator inhibitor correlated with BMI but with no other index examined. In contrast to t-PA activity and PAI, vWF responses to DDAVP inversely correlated to basal vWF concentration in all groups. Basal concentrations of vWF were increased in both type I and II diabetics and showed no relationship to degree of obesity. In summary, these results suggest that type II diabetic subjects have decreased t-PA activity, which is best explained by increased levels of PAI. The increased PAI appears related to obesity and not diabetes per se.

Original languageEnglish (US)
Pages (from-to)901-907
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume38
Issue number9
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Deamino Arginine Vasopressin
Tissue Plasminogen Activator
Plasminogen Inactivators
Diabetes Mellitus
von Willebrand Factor
Obesity
Body Mass Index
Antigens

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. / Grant, Maria B.; Fitzgerald, Connie; Guay, Colleen; Lottenberg, Richard.

In: Metabolism: Clinical and Experimental, Vol. 38, No. 9, 1989, p. 901-907.

Research output: Contribution to journalArticle

Grant, Maria B. ; Fitzgerald, Connie ; Guay, Colleen ; Lottenberg, Richard. / Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. In: Metabolism: Clinical and Experimental. 1989 ; Vol. 38, No. 9. pp. 901-907.
@article{12b2ae3e6afa46a69dce27f897927e80,
title = "Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus",
abstract = "Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor, (PAI), and von Willebrand factor (vWF) were measured in 30 diabetics and 17 control subjects. These studies were performed to clarify the role of obesity in causing abnormalities of the fibrinolytic system in diabetics. The t-PA antigen response measured after the infusion of desmopressin acetate (DDAVP) was similar in all groups. Peak responses to DDAVP for controls, type I diabetics, and type II diabetics were 21.2 ± 9.5 ng/mL, 27.5 ± 9.0 ng/mL, and 28.8 ± 11.0 ng/mL (NS), respectively. These responses did not correlate with the body mass index (BMI) or any other of the indices examined. A significant decrease of t-PA activity as contrasted with t-PA antigen following DDAVP occurred in type II diabetics only. The decrease of t-PA activity strongly correlated with greater basal levels of plasminogen activator inhibitor in these same subjects. The plasma level of plasminogen activator inhibitor correlated with BMI but with no other index examined. In contrast to t-PA activity and PAI, vWF responses to DDAVP inversely correlated to basal vWF concentration in all groups. Basal concentrations of vWF were increased in both type I and II diabetics and showed no relationship to degree of obesity. In summary, these results suggest that type II diabetic subjects have decreased t-PA activity, which is best explained by increased levels of PAI. The increased PAI appears related to obesity and not diabetes per se.",
author = "Grant, {Maria B.} and Connie Fitzgerald and Colleen Guay and Richard Lottenberg",
year = "1989",
doi = "10.1016/0026-0495(89)90239-4",
language = "English (US)",
volume = "38",
pages = "901--907",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus

AU - Grant, Maria B.

AU - Fitzgerald, Connie

AU - Guay, Colleen

AU - Lottenberg, Richard

PY - 1989

Y1 - 1989

N2 - Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor, (PAI), and von Willebrand factor (vWF) were measured in 30 diabetics and 17 control subjects. These studies were performed to clarify the role of obesity in causing abnormalities of the fibrinolytic system in diabetics. The t-PA antigen response measured after the infusion of desmopressin acetate (DDAVP) was similar in all groups. Peak responses to DDAVP for controls, type I diabetics, and type II diabetics were 21.2 ± 9.5 ng/mL, 27.5 ± 9.0 ng/mL, and 28.8 ± 11.0 ng/mL (NS), respectively. These responses did not correlate with the body mass index (BMI) or any other of the indices examined. A significant decrease of t-PA activity as contrasted with t-PA antigen following DDAVP occurred in type II diabetics only. The decrease of t-PA activity strongly correlated with greater basal levels of plasminogen activator inhibitor in these same subjects. The plasma level of plasminogen activator inhibitor correlated with BMI but with no other index examined. In contrast to t-PA activity and PAI, vWF responses to DDAVP inversely correlated to basal vWF concentration in all groups. Basal concentrations of vWF were increased in both type I and II diabetics and showed no relationship to degree of obesity. In summary, these results suggest that type II diabetic subjects have decreased t-PA activity, which is best explained by increased levels of PAI. The increased PAI appears related to obesity and not diabetes per se.

AB - Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor, (PAI), and von Willebrand factor (vWF) were measured in 30 diabetics and 17 control subjects. These studies were performed to clarify the role of obesity in causing abnormalities of the fibrinolytic system in diabetics. The t-PA antigen response measured after the infusion of desmopressin acetate (DDAVP) was similar in all groups. Peak responses to DDAVP for controls, type I diabetics, and type II diabetics were 21.2 ± 9.5 ng/mL, 27.5 ± 9.0 ng/mL, and 28.8 ± 11.0 ng/mL (NS), respectively. These responses did not correlate with the body mass index (BMI) or any other of the indices examined. A significant decrease of t-PA activity as contrasted with t-PA antigen following DDAVP occurred in type II diabetics only. The decrease of t-PA activity strongly correlated with greater basal levels of plasminogen activator inhibitor in these same subjects. The plasma level of plasminogen activator inhibitor correlated with BMI but with no other index examined. In contrast to t-PA activity and PAI, vWF responses to DDAVP inversely correlated to basal vWF concentration in all groups. Basal concentrations of vWF were increased in both type I and II diabetics and showed no relationship to degree of obesity. In summary, these results suggest that type II diabetic subjects have decreased t-PA activity, which is best explained by increased levels of PAI. The increased PAI appears related to obesity and not diabetes per se.

UR - http://www.scopus.com/inward/record.url?scp=0024438124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024438124&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(89)90239-4

DO - 10.1016/0026-0495(89)90239-4

M3 - Article

C2 - 2505017

AN - SCOPUS:0024438124

VL - 38

SP - 901

EP - 907

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -